Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is a global biopharmaceutical leader driving innovation in immunology, oncology, and neuroscience therapies. This page provides real-time access to AbbVie's official press releases, regulatory milestones, and strategic developments.
Investors and industry professionals will find a curated collection of earnings reports, FDA approval updates, clinical trial results, and partnership announcements. Our comprehensive resource eliminates the need to track multiple sources, offering verified information directly from corporate communications and trusted financial publications.
Key content includes updates on AbbVie's R&D pipeline, mergers & acquisitions like the Allergan integration, patent developments, and market expansion initiatives. All materials are organized chronologically for efficient analysis of the company's trajectory.
Bookmark this page for streamlined monitoring of AbbVie's operational and financial performance. Check back regularly to stay informed about developments impacting one of the pharmaceutical sector's most influential innovators.
AbbVie announced new data presented at EULAR 2021, showing RINVOQ (upadacitinib) 15 mg leads to higher rates of clinical remission and low disease activity in moderate to severe rheumatoid arthritis patients compared to HUMIRA (adalimumab) over three years. Clinical remission was achieved in 32% of RINVOQ patients versus 22% with HUMIRA. The safety profile of RINVOQ remained consistent over 4.5 years, with no new risks identified. Overall, this data reinforces the efficacy and safety of RINVOQ as a treatment option.
AbbVie (NYSE: ABBV) will participate in Bernstein's 37th Annual Strategic Decisions Conference on June 2, 2021, at 2:30 p.m. Central Time. Presenters will include Michael Severino, M.D., vice chairman and president, and Robert A. Michael, executive vice president and CFO. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived edition posted later the same day. AbbVie is committed to developing innovative medicines across various therapeutic areas, including immunology, oncology, and neurology.
AbbVie (NYSE: ABBV) will present key data from its migraine portfolio at the 2021 American Headache Society Annual Scientific Meeting, scheduled for June 3-6. A total of 23 abstracts, including four podium presentations, will cover significant findings on preventive and acute migraine treatments, highlighting atogepant and UBRELVY®. Dr. Mitchell Mathis emphasized the importance of these advancements in addressing the debilitating impact of migraines on millions. Presentations will include studies on treatment gaps, efficacy, and patient quality of life, showcasing AbbVie's commitment to the migraine community.
AbbVie (NYSE: ABBV) announced it will present 41 abstracts on its immunology assets at the EULAR 2021 Virtual Congress from June 2-5. Key data includes RINVOQ efficacy and safety results for rheumatoid arthritis (RA) and psoriatic arthritis (PsA) from one to three years. Additionally, integrated safety data from Phase 3 SELECT trials for RINVOQ will be discussed, highlighting AbbVie's focus on advancing treatment for rheumatic diseases. The company's commitment to innovation in rheumatology is underscored by these presentations.
AbbVie (NYSE: ABBV) has received European Commission approval for VENCLYXTO (venetoclax) in combination with hypomethylating agents azacitidine or decitabine. This treatment is aimed at adult patients with newly diagnosed acute myeloid leukemia (AML) who cannot undergo intensive chemotherapy. The approval applies to all 27 EU member states, Iceland, Liechtenstein, and Norway. Clinical trials indicate that this combination improves overall survival compared to azacitidine alone, marking a significant advancement in AML treatment options.
AbbVie presented late-breaking data from two Phase 3 studies, ADVANCE and MOTIVATE, at the DDW 2021 Conference, showcasing the efficacy of investigational drug risankizumab in treating moderately to severely active Crohn's disease. Patients receiving 600 mg or 1200 mg of risankizumab demonstrated significantly higher rates of clinical remission and endoscopic response compared to placebo, with p-values <0.001. The safety profile was consistent with previous trials, showing lower rates of serious adverse events compared to placebo. Results are submitted for publication, with ongoing studies for maintenance therapy.
On May 24, 2021, AbbVie announced that The Lancet published primary analysis results from pivotal Phase 3 clinical trials (Measure Up 1, Measure Up 2, and AD Up) assessing RINVOQ (upadacitinib) for treating moderate to severe atopic dermatitis in adults and adolescents. The studies demonstrated that RINVOQ met all primary and secondary endpoints, showcasing its efficacy and safety when compared to placebo. The results indicate potential advancements in treatment options for atopic dermatitis, affecting a significant percentage of the population.
AbbVie will participate in the UBS Global Healthcare Virtual Conference on May 25, 2021, at 11:00 a.m. Central time. Key executives participating include Michael Severino, Robert A. Michael, and Jeffrey R. Stewart. A live audio webcast will be available on AbbVie’s Investor Relations website, with an archived version accessible later the same day. AbbVie is dedicated to developing innovative medicines across various therapeutic areas such as immunology, oncology, and neuroscience.
AbbVie (NYSE: ABBV) will present results from 43 abstracts across 12 cancers at the ASCO Annual Meeting (June 4-8) and EHA Congress (June 9-17). Key presentations include data on the CAPTIVATE study concerning chronic lymphocytic leukemia (CLL) patients treated with an ibrutinib and venetoclax combination. Notable highlights include long-term data from various trials such as CLL14 and MURANO. These presentations aim to advance blood cancer treatment and showcase AbbVie's expanding oncology portfolio, reflecting its commitment to improving patient outcomes.
AbbVie (NYSE: ABBV) will present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 3:50 p.m. Central time. Key executives, including Michael Severino, Robert A. Michael, and Jeffrey R. Stewart, will participate in the virtual event. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version accessible later that day. AbbVie focuses on innovative medicines in immunology, oncology, neuroscience, and more.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
